Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
16/06/2026 13:52
BRIEF-Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry June 16 (Reuters) - Intelligent Bio Solutions Inc INBS.O:
INTELLIGENT BIO SOLUTIONS INITIATES CLINICAL STUDY SUPPORTING FDA CLEARANCE AND PLANNED U.S. MARKET ENTRY
INTELLIGENT BIO SOLUTIONS - EXPECTS TO COMPLETE INTERFERENCE STUDY BY MID-JULY 2026 FOR FDA 510(K) SUBMISSION
Source text: ID:nGNXbjT8hX
Further company coverage: INBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study